Related Experiment Video
Updated: Apr 16, 2026
07:40
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
18.9K
Multistage adaptive biomarker-directed targeted design for randomized clinical trials
Zhong Gao1, Anindya Roy1, Ming Tan2
1Department of Mathematics and Statistics, University of Maryland, Baltimore County, Baltimore, MD 21250, United States.
Contemporary Clinical Trials
|March 18, 2015
Summary
Multistage adaptive designs enhance targeted clinical trials by improving efficiency and data collection. Careful consideration of biomarker performance is crucial for accurate early stopping decisions in these precision medicine studies.
Area of Science:
- Biostatistics
- Clinical Trial Design
- Precision Medicine
Background:
- Precision medicine revolutionizes patient treatment and therapy development.
- Biomarker-directed targeted designs identify patient subpopulations with specific disease etiologies.
- Multistage testing integration enhances targeted trial flexibility through sequential monitoring and stochastic curtailment.
Purpose of the Study:
- To evaluate a multistage adaptive design for targeted clinical trials.
- To assess the design's efficiency, information accumulation, and conditional power.
- To investigate the impact of biomarker performance on the adaptive design's effectiveness.
Main Methods:
- Studied a multistage adaptive design for targeted trials with continuous or binary endpoints.
- Utilized Brownian motion approximation for test statistic distributions in targeted trials.
- Compared the targeted multistage design against its untargeted counterpart.
Main Results:
- The targeted multistage design demonstrated improved study efficiency, information accumulation, and conditional power.
- Biomarker performance, including sensitivity and specificity, significantly influences trial efficiency and power.
- Imperfect biomarker performance can lead to over-estimated conditional power and invalid early stopping decisions.
Conclusions:
- Multistage adaptive designs offer enhanced flexibility for targeted trials through multistage testing and early stopping.
- These designs maintain the statistical rigor of clinical studies.
- Statistical planning must carefully consider biomarker performance for optimal trial outcomes.
Related Concept Videos
01:20Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
387
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
387
01:15Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
396
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
396
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
353
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
353
01:11Clinical Trials: Overview
5.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.5K
01:16Clinical Trials
11.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
11.2K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
579
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
579